BCG 疫苗市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、應用、配銷通路、地區和競爭細分，2020-2030 年

2024 年全球 BCG 疫苗市場價值為 1.4556 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 5.90%。全球 BCG（卡介苗）疫苗市場在公共衛生領域發揮著至關重要的作用，主要是作為預防結核病 (TB) 的第一線防線。卡介苗歷史悠久、用途廣泛，至今仍是全球對抗結核病的重要工具。從歷史上看，卡介苗是在 20 世紀初開發的，是第一個成功的抗結核病疫苗。自那時起，全球已有數百萬人接種了該疫苗，成為史上使用最廣泛的疫苗之一。結核病是一種主要影響肺部的傳染性細菌感染，它繼續對全球健康構成重大挑戰，特別是在醫療資源有限的地區。

全球卡介苗市場的一個主要特徵是它被納入許多國家的免疫計劃中。政府主導的措施和要求確保世界相當一部分人口能夠接種卡介苗，通常作為嬰兒出生時的劑量。早期接種疫苗是一項重要的預防措施，可以預防結核病並降低嚴重疾病的風險，尤其是對兒童而言。除了傳統的結核病預防作用外，正在進行的研究和開發工作正在擴大卡介苗的潛在應用。例如，人們正在探索孕產婦免疫接種作為一種保護母親和嬰兒免受結核病以外的各種感染（如呼吸道疾病）影響的方法。

主要市場促進因素

發展中國家和低度開發國家結核病發生率不斷上升

主要市場挑戰

供應鏈中斷

主要市場趨勢

新出現的結核病菌株

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球卡介苗市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（免疫 BCG、治療 BCG）
  • 依應用（結核病、膀胱癌）
  • 按配銷通路（醫院、診所、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美 BCG 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第7章：歐洲卡介苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區卡介苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲 BCG 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲 BCG 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球 BCG 疫苗市場：SWOT 分析

第 14 章：競爭格局

• Serum Institute of India Pvt. Ltd.
• GreenSignal Bio Pharma Ltd
• Taj Pharmaceuticals Limited
• Japan BCG Laboratory
• Merck & Co., Inc.
• Microgen LLC
• Biomed Lublin SA
• BCG Vaccine Laboratory
• China Biotechnology Co., Ltd.
• AJ Biologics Sdn Bhd

第 15 章：策略建議

第16章調查會社について,免責事項

Global BCG Vaccines Market was valued at USD 145.56 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.90% through 2030. The global BCG (Bacillus Calmette-Guerin) vaccine market plays a crucial role in the realm of public health, primarily as a frontline defense against tuberculosis (TB). With its rich history and widespread usage, the BCG vaccine remains a vital tool in the global fight against TB. Historically, the BCG vaccine was developed in the early 20th century as the first successful vaccine against TB. Since then, it has been administered to millions of individuals worldwide, making it one of the most widely used vaccines in history. TB, a contagious bacterial infection that primarily affects the lungs, continues to pose a significant global health challenge, particularly in regions with limited access to healthcare resources.

One of the key features of the global BCG vaccine market is its inclusion in the immunization programs of many countries. Government-led initiatives and mandates ensure that a substantial portion of the world's population receives the BCG vaccine, often as a birth dose to infants. This early vaccination serves as a crucial preventive measure, offering protection against TB and reducing the risk of severe forms of the disease, particularly in children. In addition to its traditional role in TB prevention, ongoing research and development efforts are expanding the potential applications of the BCG vaccine. Maternal immunization, for example, is being explored as a means to provide both mothers and infants with protection against various infections beyond TB, such as respiratory illnesses.

Key Market Drivers

Increasing Prevalence of Tuberculosis in Developing and under-developed countries

The increasing prevalence of tuberculosis (TB) in developing and underdeveloped countries is a significant driver for the growth of the Bacillus Calmette-Guerin (BCG) vaccine market. For instance, in February 2022, the Ministry of Health and Family Welfare, Government of India, published the "India TB Report 2022." The report highlighted that pediatric tuberculosis remains a significant concern, contributing to approximately 31% of the global TB burden. As a result, the increasing BCG vaccination rate among children is expected to drive higher immunization coverage within the target population. This growing emphasis on BCG vaccination for pediatric TB prevention is anticipated to boost market expansion, supporting efforts to combat tuberculosis more effectively. BCG is a widely used vaccine for the prevention of tuberculosis, and its demand is directly linked to the TB burden in these regions. Here's how the rising TB prevalence contributes to the expansion of the BCG vaccine market: Developing and underdeveloped countries often face higher TB incidence rates due to various factors such as overcrowding, limited access to healthcare, and weakened immune systems among their populations. TB remains a critical public health issue in these regions, making vaccination a crucial strategy for prevention.

Key Market Challenges

Supply chain disruptions

Supply chain disruptions have emerged as a significant challenge for the BCG (Bacillus Calmette-Guerin) vaccine market, impacting the production, distribution, and availability of this critical immunization tool. These disruptions, often stemming from various global factors, have far-reaching consequences for the global efforts to combat tuberculosis (TB) through BCG vaccination. The manufacturing of vaccines like BCG requires a complex supply chain, including the procurement of specific raw materials. Disruptions in the availability of these materials, often due to factors like trade restrictions, natural disasters, or geopolitical tensions, can hinder vaccine production.

The BCG vaccine is produced in select facilities and then distributed globally. Interruptions in transportation networks, such as those caused by the COVID-19 pandemic, can lead to delays in the delivery of vaccines to their intended destinations. These delays can impact vaccination programs and contribute to vaccine shortages. BCG vaccines, like many other vaccines, require strict temperature control throughout the supply chain to maintain their efficacy. Any interruptions or failures in the cold chain, whether due to equipment malfunctions or logistical challenges, can render vaccines ineffective and result in wastage. Ensuring an adequate supply of BCG vaccines relies on the capacity of manufacturing facilities. Disruptions caused by issues such as equipment breakdowns or regulatory obstacles can limit the production volume, leading to supply shortages. Political tensions and trade disputes can affect the movement of vaccines and their components across borders. Export restrictions and tariffs can disrupt the flow of vaccines, exacerbating supply chain challenges.

Key Market Trends

Emerging TB strains

Emerging strains of tuberculosis (TB) have become a concerning trend in recent years, posing a significant challenge to TB control efforts and the Bacillus Calmette-Guerin (BCG) vaccine market. Several factors contribute to the emergence of new TB strains, which are increasingly drug-resistant and harder to treat: The overuse and misuse of antibiotics have led to the development of drug-resistant TB strains. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are particularly worrisome. These strains do not respond to first-line TB drugs, making treatment more complex, lengthy, and expensive.

In an interconnected world with increased global travel and population mobility, TB strains can easily cross borders. Infected individuals may carry drug-resistant TB strains with them, introducing these strains to new regions and populations. Immune-compromised individuals, such as those living with HIV/AIDS, are more susceptible to TB and its drug-resistant forms. This population provides fertile ground for the emergence and spread of TB strains that are more resistant to treatment. Weakened TB control programs in some regions may contribute to the persistence and spread of TB. Inadequate diagnosis, treatment, and infection control measures can allow drug-resistant strains to flourish. TB is a genetically diverse bacterium, and its strains can vary in virulence and resistance. The BCG vaccine, derived from a specific strain, may offer limited protection against some of these diverse TB strains. Advancements in genomics and molecular epidemiology have improved our ability to track and analyze TB strains. Researchers can now identify and characterize emerging strains more effectively, enabling targeted responses and treatment strategies.

Key Market Players

• Serum Institute of India Pvt. Ltd.
• GreenSignal Bio Pharma Ltd
• Taj Pharmaceuticals Limited
• Japan BCG Laboratory
• Merck & Co., Inc.
• Microgen LLC
• Biomed Lublin S.A.
• BCG Vaccine Laboratory
• China Biotechnology Co., Ltd.
• AJ Biologics Sdn Bhd

Report Scope:

In this report, the Global BCG Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

BCG Vaccines Market, By Product:

• Immune BCG
• Therapy BCG

BCG Vaccines Market, By Application:

• Tuberculosis
• Bladder Cancer

BCG Vaccines Market, By Distribution Channel:

• Hospitals
• Clinics
• Others

BCG Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the BCG Vaccines Market.

Available Customizations:

Global BCG Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global BCG Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Immune BCG, Therapy BCG)
  • 5.2.2. By Application (Tuberculosis, Bladder Cancer)
  • 5.2.3. By Distribution Channel (Hospitals, Clinics, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America BCG Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States BCG Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada BCG Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico BCG Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe BCG Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany BCG Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom BCG Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy BCG Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France BCG Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain BCG Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific BCG Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China BCG Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India BCG Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan BCG Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea BCG Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia BCG Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. South America BCG Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil BCG Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina BCG Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia BCG Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa BCG Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa BCG Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia BCG Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE BCG Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisition

13. Global BCG Vaccine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Serum Institute of India Pvt. Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Treatment Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. GreenSignal Bio Pharma Ltd
• 14.3. Taj Pharmaceuticals Limited
• 14.4. Japan BCG Laboratory
• 14.5. Merck & Co., Inc.
• 14.6. Microgen LLC
• 14.7. Biomed Lublin S.A.
• 14.8. BCG Vaccine Laboratory
• 14.9. China Biotechnology Co., Ltd.
• 14.10.AJ Biologics Sdn Bhd

15. Strategic Recommendations

16. About Us & Disclaimer